CSIMarket
 
Biocryst Pharmaceuticals Inc   (NASDAQ: BCRX)
Other Ticker:  
 
 
Price: $7.4000 $0.36 5.114%
Day's High: $7.41 Week Perf: 9.31 %
Day's Low: $ 6.96 30 Day Perf: -4.39 %
Volume (M): 3,145 52 Wk High: $ 9.50
Volume (M$): $ 23,275 52 Wk Avg: $7.33
Open: $6.99 52 Wk Low: $4.03



 Market Capitalization (Millions $) 1,530
 Shares Outstanding (Millions) 207
 Employees 197
 Revenues (TTM) (Millions $) 451
 Net Income (TTM) (Millions $) -89
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 1

Biocryst Pharmaceuticals Inc
Biocryst Pharmaceuticals Inc.
is a biotechnology company based in Durham, North Carolina that focuses on developing innovative drugs for the treatment of rare diseases.
The company primarily focuses on developing small-molecule drugs designed to target specific enzymes or proteins in the body that are involved in the disease process.
Biocryst's current pipeline includes a diverse range of drug candidates, including orally-administered treatments for hereditary angioedema (HAE), a rare genetic disorder that causes sudden and severe swelling attacks; Alport syndrome, a rare genetic disorder that affects the kidneys and can lead to kidney failure; and non-alcoholic steatohepatitis (NASH), a type of liver disease that is associated with obesity and diabetes.
Their lead candidate is Orladeyo, an oral medication approved by the FDA for the prevention of HAE attacks in adults and adolescents over the age of 12.
Biocryst is also continuing to work on new indications for Orladeyo and is exploring the potential for it to be used in combination with other medications or as a monotherapy.
Another key focus area for Biocryst is developing antiviral drugs.
They have several candidates in their program, including Galidesivir, which has shown promise in treating a number of viral diseases, including influenza, Ebola, and most recently, COVID-19.
Overall, Biocryst Pharmaceuticals Inc.
has a strong track record of developing innovative drugs to treat rare diseases, and their ongoing research and development efforts position them as a leader in the biotechnology industry.


   Company Address: 4505 Emperor Blvd., Suite 200 Durham 27703 NC
   Company Phone Number: 859-1302   Stock Exchange / Ticker: NASDAQ BCRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.04%    
BIIB        2.99% 
CRSP        11.64% 
EXEL        3.4% 
GILD        0.88% 
MRNA   -1.61%    
• View Complete Report
   



Clinical Study

Breakthrough in Hereditary Angioedema Management BioCrysts ORLADEYO Demonstrates Efficacy in Pediatric Patients and ...

Published Mon, Feb 24 2025 11:40 AM UTC

Recent advancements in the field of hereditary angioedema (HAE) prophylaxis have emerged, underscoring the critical need for safer, more effective treatment options for patients affected by this condition. BioCryst Pharmaceuticals, Inc. has made significant strides in this regard with its novel oral therapy, ORLADEYO (berotralstat). The company has announced compelling data ...

Shares

BioCryst Pharmaceuticals Strengthens Workforce Through Strategic Inducement Grants Amid Sturdy Market Position,

Published Tue, Feb 4 2025 12:00 PM UTC

BioCryst Pharmaceuticals Boosts Talent Acquisition with New Inducement GrantsBioCryst Pharmaceuticals, Inc., headquartered in Research Triangle Park, N.C., is charting a strategic course to enhance its workforce and drive innovation in the biopharmaceutical sector. According to a recent press release dated February 4, 2025, the company announced significant inducement grant...

Shares

BioCryst Pharmaceuticals, Inc Embraces Growth with Strategic Inducement Grants: An Overview of Recent Developments

Published Wed, Dec 4 2024 9:15 PM UTC

BioCryst Pharmaceuticals, Inc. Embraces Growth with Strategic Inducement Grants: An Overview of Recent DevelopmentsBioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), a company renowned for its innovations in drug development for rare diseases, has announced a series of inducement grants awarded to newly hired employees over the past few months. These grants, consisting of stock ...

Product Service News

BioCryst Pharmaceuticals Launches ORLADEYO in Ireland, Pioneering Advances in Hereditary Angioedema Treatment,

Published Mon, Nov 18 2024 7:00 AM UTC

RESEARCH TRIANGLE PARK, N.C. BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is making significant strides in treating hereditary angioedema (HAE), a debilitating genetic disorder characterized by recurrent episodes of severe swelling. As of November 18, 2024, the company has announced the Health Services Executive (HSE) in Ireland s endorsement of ORLADEYO (berotralstat) fo...

Stock Market Announcement

BioCryst Pharmaceuticals Amplifies Workforce Investment with New Inducement Grants Amid Sustained Growth Strategy,

Published Tue, Nov 5 2024 12:01 PM UTC

RESEARCH TRIANGLE PARK, N.C. BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is making significant strides in its efforts to attract and retain top talent, as evidenced by a series of recent stock option and restricted stock unit (RSU) grants to newly hired employees. The company?s compensation committee has authorized these grants in line with Nasdaq Listing Rule 5635(c)(4)...







Biocryst Pharmaceuticals Inc's Segments
Product sales net    99.13 % of total Revenue
Collaborative and other revenues    0.87 % of total Revenue

  Biocryst Pharmaceuticals Inc Outlook

On January 5 2024 the Biocryst Pharmaceuticals Inc provided following guidance

Biocryst Pharmaceuticals Inc. has recently revealed its preliminary full year 2023 net revenue for ORLADEYO (berotralstat) drug, amounting to $325 million. This figure reflects a notable 29 percent increase ...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com